Pharmaceutical reimbursement assessment committee evaluated whether benefits of anticancer drugs were appropriate

On July 10, pharmaceutical reimbursement assessment committee of Health Insurance Review and Assessment Committee evaluated whether benefits of anticancer drugs were appropriate.

First, Astellas Pharmaceutical Korea's 'Xtandi' passed the committee in the way of reimbursement for risk-sharing. It should reimburse a certain percentage of the drug's benefits to HIRA. This drug is used in treating...